vs
Astrana Health, Inc.（ASTH）与欧加隆（OGN）财务数据对比。点击上方公司名可切换其他公司
欧加隆的季度营收约是Astrana Health, Inc.的1.6倍（$1.5B vs $950.5M），Astrana Health, Inc.净利率更高（0.7% vs -13.6%，领先14.3%），Astrana Health, Inc.同比增速更快（42.9% vs -5.3%），欧加隆自由现金流更多（$96.0M vs $-6.0M），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs -3.6%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
欧加隆是一家总部位于美国新泽西州泽西城的制药企业，核心业务覆盖生殖医学、避孕、精神科、激素替代疗法及麻醉领域的药物研发与生产。公司所有产品均在美国境外生产，同时美国市场贡献了其三分之一的营收。
ASTH vs OGN — 直观对比
营收规模更大
OGN
是对方的1.6倍
$950.5M
营收增速更快
ASTH
高出48.2%
-5.3%
净利率更高
ASTH
高出14.3%
-13.6%
自由现金流更多
OGN
多$102.0M
$-6.0M
两年增速更快
ASTH
近两年复合增速
-3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $1.5B |
| 净利润 | $6.6M | $-205.0M |
| 毛利率 | — | 49.2% |
| 营业利润率 | 1.9% | -9.8% |
| 净利率 | 0.7% | -13.6% |
| 营收同比 | 42.9% | -5.3% |
| 净利润同比 | 184.4% | -288.1% |
| 每股收益（稀释后） | $0.12 | $-0.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHOGN
| Q4 25 | $950.5M | $1.5B | ||
| Q3 25 | $956.0M | $1.6B | ||
| Q2 25 | $654.8M | $1.6B | ||
| Q1 25 | $620.4M | $1.5B | ||
| Q4 24 | $665.2M | $1.6B | ||
| Q3 24 | $478.7M | $1.6B | ||
| Q2 24 | $486.3M | $1.6B | ||
| Q1 24 | $404.4M | $1.6B |
净利润ASTHOGN
| Q4 25 | $6.6M | $-205.0M | ||
| Q3 25 | $373.0K | $160.0M | ||
| Q2 25 | $9.4M | $145.0M | ||
| Q1 25 | $6.7M | $87.0M | ||
| Q4 24 | $-7.8M | $109.0M | ||
| Q3 24 | $16.1M | $359.0M | ||
| Q2 24 | $19.2M | $195.0M | ||
| Q1 24 | $14.8M | $201.0M |
毛利率ASTHOGN
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% | ||
| Q1 24 | — | 59.0% |
营业利润率ASTHOGN
| Q4 25 | 1.9% | -9.8% | ||
| Q3 25 | 2.0% | 15.2% | ||
| Q2 25 | 3.1% | 14.4% | ||
| Q1 25 | 3.3% | 6.7% | ||
| Q4 24 | 0.1% | 8.1% | ||
| Q3 24 | 5.9% | 13.1% | ||
| Q2 24 | 6.2% | 14.6% | ||
| Q1 24 | 7.5% | 14.5% |
净利率ASTHOGN
| Q4 25 | 0.7% | -13.6% | ||
| Q3 25 | 0.0% | 10.0% | ||
| Q2 25 | 1.4% | 9.1% | ||
| Q1 25 | 1.1% | 5.8% | ||
| Q4 24 | -1.2% | 6.8% | ||
| Q3 24 | 3.4% | 22.7% | ||
| Q2 24 | 3.9% | 12.1% | ||
| Q1 24 | 3.7% | 12.4% |
每股收益（稀释后）ASTHOGN
| Q4 25 | $0.12 | $-0.78 | ||
| Q3 25 | $0.01 | $0.61 | ||
| Q2 25 | $0.19 | $0.56 | ||
| Q1 25 | $0.14 | $0.33 | ||
| Q4 24 | $-0.14 | $0.42 | ||
| Q3 24 | $0.33 | $1.38 | ||
| Q2 24 | $0.40 | $0.75 | ||
| Q1 24 | $0.31 | $0.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | $574.0M |
| 总债务越低越好 | — | $8.6B |
| 股东权益账面价值 | $779.3M | $752.0M |
| 总资产 | $2.2B | $12.9B |
| 负债/权益比越低杠杆越低 | — | 11.49× |
8季度趋势，按日历期对齐
现金及短期投资ASTHOGN
| Q4 25 | $429.5M | $574.0M | ||
| Q3 25 | $463.4M | $672.0M | ||
| Q2 25 | $342.1M | $599.0M | ||
| Q1 25 | $260.9M | $547.0M | ||
| Q4 24 | $290.8M | $675.0M | ||
| Q3 24 | $350.3M | $763.0M | ||
| Q2 24 | $327.7M | $704.0M | ||
| Q1 24 | $337.3M | $575.0M |
总债务ASTHOGN
| Q4 25 | — | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B | ||
| Q1 24 | — | $8.7B |
股东权益ASTHOGN
| Q4 25 | $779.3M | $752.0M | ||
| Q3 25 | $775.5M | $906.0M | ||
| Q2 25 | $765.5M | $733.0M | ||
| Q1 25 | $745.4M | $542.0M | ||
| Q4 24 | $712.7M | $472.0M | ||
| Q3 24 | $704.6M | $493.0M | ||
| Q2 24 | $678.9M | $144.0M | ||
| Q1 24 | $653.5M | $48.0M |
总资产ASTHOGN
| Q4 25 | $2.2B | $12.9B | ||
| Q3 25 | $2.2B | $13.6B | ||
| Q2 25 | $1.4B | $13.5B | ||
| Q1 25 | $1.3B | $13.2B | ||
| Q4 24 | $1.4B | $13.1B | ||
| Q3 24 | $1.3B | $12.8B | ||
| Q2 24 | $1.3B | $12.2B | ||
| Q1 24 | $1.2B | $11.9B |
负债/权益比ASTHOGN
| Q4 25 | — | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | — | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× | ||
| Q1 24 | — | 181.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $141.0M |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | $96.0M |
| 自由现金流率自由现金流/营收 | -0.6% | 6.4% |
| 资本支出强度资本支出/营收 | 0.3% | 3.0% |
| 现金转化率经营现金流/净利润 | -0.44× | — |
| 过去12个月自由现金流最近4个季度 | $104.5M | $538.0M |
8季度趋势，按日历期对齐
经营现金流ASTHOGN
| Q4 25 | $-2.9M | $141.0M | ||
| Q3 25 | $10.0M | $264.0M | ||
| Q2 25 | $90.9M | $220.0M | ||
| Q1 25 | $16.6M | $75.0M | ||
| Q4 24 | $-10.9M | $390.0M | ||
| Q3 24 | $34.0M | $141.0M | ||
| Q2 24 | $23.2M | $332.0M | ||
| Q1 24 | $6.0M | $76.0M |
自由现金流ASTHOGN
| Q4 25 | $-6.0M | $96.0M | ||
| Q3 25 | $7.4M | $218.0M | ||
| Q2 25 | $89.5M | $181.0M | ||
| Q1 25 | $13.6M | $43.0M | ||
| Q4 24 | $-13.5M | $335.0M | ||
| Q3 24 | $31.7M | $99.0M | ||
| Q2 24 | $20.4M | $300.0M | ||
| Q1 24 | $5.6M | $30.0M |
自由现金流率ASTHOGN
| Q4 25 | -0.6% | 6.4% | ||
| Q3 25 | 0.8% | 13.6% | ||
| Q2 25 | 13.7% | 11.4% | ||
| Q1 25 | 2.2% | 2.8% | ||
| Q4 24 | -2.0% | 21.0% | ||
| Q3 24 | 6.6% | 6.3% | ||
| Q2 24 | 4.2% | 18.7% | ||
| Q1 24 | 1.4% | 1.8% |
资本支出强度ASTHOGN
| Q4 25 | 0.3% | 3.0% | ||
| Q3 25 | 0.3% | 2.9% | ||
| Q2 25 | 0.2% | 2.4% | ||
| Q1 25 | 0.5% | 2.1% | ||
| Q4 24 | 0.4% | 3.5% | ||
| Q3 24 | 0.5% | 2.7% | ||
| Q2 24 | 0.6% | 2.0% | ||
| Q1 24 | 0.1% | 2.8% |
现金转化率ASTHOGN
| Q4 25 | -0.44× | — | ||
| Q3 25 | 26.69× | 1.65× | ||
| Q2 25 | 9.65× | 1.52× | ||
| Q1 25 | 2.48× | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | 2.11× | 0.39× | ||
| Q2 24 | 1.21× | 1.70× | ||
| Q1 24 | 0.40× | 0.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
OGN
暂无分部数据
